Cardiac parasympathetic dysfunction in the early phase of Parkinson’s disease
- 354 Downloads
Cardiac parasympathetic function is strongly affected by aging. Although sympathetic dysfunction has been well documented in Parkinson’s disease (PD), cardiac parasympathetic dysfunction has not been well studied. The objective of this study was to clarify the development of cardiac parasympathetic dysfunction in the early phase of PD and to explore the age-corrected correlation between cardiac parasympathetic dysfunction and cardiac sympathetic dysfunction. We reviewed 25 healthy controls and 56 patients with idiopathic PD of Hoehn and Yahr stages I–III. We evaluated cardiac parasympathetic function using the Valsalva ratio, the baroreflex sensitivity (BRS) and the coefficient of variation of RR intervals in the resting state (resting-CVRR) and during deep breathing (DB-CVRR). In addition, we measured cardiac 123I-metaiodobenzylguanidine (MIBG) uptake to investigate the relationship between cardiac sympathetic and parasympathetic dysfunction in PD. Compared with healthy controls, patients with PD showed significantly decreased cardiac parasympathetic parameters (resting-CVRR 2.8 ± 1.3 vs. 1.7 ± 0.6%, p < 0.001; DB-CVRR 5.8 ± 2.3 vs. 3.8 ± 1.7%, p < 0.001; Valsalva ratio 1.52 ± 0.26 vs. 1.34 ± 0.17, p < 0.01; BRS 10.6 ± 9.5 vs. 5.0 ± 5.4 ms/mmHg, p < 0.01). In particular, resting-CVRR and DB-CVRR were significantly decreased in the early phase of PD. In age-corrected analyses, none of the parasympathetic indices correlated with the delayed cardiac 123I-MIBG uptake. These observations indicate that cardiac parasympathetic dysfunction occurs in the early phase of PD, but not necessarily in parallel with cardiac sympathetic dysfunction.
KeywordsParkinson’s disease Cardiac parasympathetic dysfunction Cardiac 123I-metaiodobenzylguanidine scintigraphy Autonomic dysfunction Autonomic nervous system
Compliance with ethical standards
This work was supported by JSPS KAKENHI Grant Nos. JP24590691, JP16K09713; and Grants from the Ministry of Health, Labor and Welfare of Japan.
Financial disclosure/conflicts of interest
None of the authors reports any financial interests or potential conflicts of interest.
- 5.Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53(2–3):230–234CrossRefPubMedGoogle Scholar
- 9.Oka H, Yoshioka M, Morita M, Mochio S, Inoue K (2003) Cardiac sympathetic dysfunction in Parkinson’s disease–relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver. Rinsho Shinkeigaku Clin Neurol 43(8):465–469Google Scholar
- 14.Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Euro Heart J 17(3):354–381Google Scholar
- 21.Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res Off J Clin Auton Res Soc 21(2):69–72. doi: 10.1007/s10286-011-0119-5 CrossRefGoogle Scholar
- 23.Kallio M, Haapaniemi T, Turkka J, Suominen K, Tolonen U, Sotaniemi K, Heikkila VP, Myllyla V (2000) Heart rate variability in patients with untreated Parkinson’s disease. Euro J Neurol Off J Euro Fed Neurol Soc 7(6):667–672Google Scholar
- 25.Gjerloff T, Fedorova T, Knudsen K, Munk OL, Nahimi A, Jacobsen S, Danielsen EH, Terkelsen AJ, Hansen J, Pavese N, Brooks DJ, Borghammer P (2015) Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain J Neurol 138(Pt 3):653–663. doi: 10.1093/brain/awu369 CrossRefGoogle Scholar
- 29.Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119(6):689–702. doi: 10.1007/s00401-010-0664-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL (2008) Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience 153(3):733–750. doi: 10.1016/j.neuroscience.2008.02.074 CrossRefPubMedPubMedCentralGoogle Scholar